Vancouver, B.C. – January 13, 2023 – Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”) announces appointment of Michael Galego as interim Chief Executive Officer of the Company. Alexander Somjen has resigned as Chief Executive Officer of the Company, effective today, to pursue other opportunities. The Company would like to thank Mr. Somjen for his service to the Company and wish him success in his future endeavors.
About Origin Therapeutics
Origin Therapeutics is an investment issuer that has historically focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. On December 8, 2022, the Company announced that its Board of Directors had initiated a review process to consider, review and evaluate strategic alternatives for the Company.
For Further Information:
Chief Financial Officer and Corporate Secretary Origin Therapeutics Holdings Inc.
Forward-Looking Information and Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Except as required by applicable law, the Company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.